This week’s podcast is sponsored by Scientist.com. The mainstream media in the past couple of months has picked up on artificial intelligence (AI). The coverage concentrates not so much on…
Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons.…
Cell products providing a scalable source of human cells can now help scientists study neurogenerative diseases in human context. UK-based, cell-coding company, bit.bio announced the expansion to its portfolio today…